Jinsun Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jinsun Park has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Gi-Byoung Nam
Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
4 shared publications - Min Soo Cho
Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3 shared publications - Myung-Jin Cha
Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea
3 shared publications - Chang Hee Kwon
Division of Cardiology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea
2 shared publications - Hong Euy Lim
Division of Cardiology, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea
2 shared publications Il‐Young Oh
Cardiovascular Center Seoul National University Bundang Hospital, Seoul National University College of Medicine Seongnam Republic of Korea
2 shared publications
Latest Publications
- 6 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Predictors of Early Versus Late Atrial Tachyarrhythmia Recurrence After Cryoballoon Ablation by Atrial Fibrillation Type
Introduction: Patient characteristics and predictors of early (ERAT) and late (LRAT) recurrence of atrial tachyarrhythmia by atrial fibrillation (AF) type after cryoballoon ablation (CBA) remain poorly defined. Methods: Using the Korean Heart Rhythm Cryoballoon Registry (12 centers, 2018–2022), 2051 patients undergoing CBA for drug‐refractory AF were stratified by AF type. ERAT was defined as atrial tachyarrhythmia within the 3‐month blanking period and LRAT as recurrence beyond 3 months. Independent predictors of ERAT (all patients) and LRAT (patients without ERAT) were identified. Results: ERAT occurred in 631 patients (30.8%; 17.6% in paroxysmal and 40.4% in persistent AF). Among 1420 patients without ERAT, LRAT occurred in 311 (21.9%; 16.7% paroxysmal, 27.2% persistent). In paroxysmal AF, coronary artery disease (HR 1.60; 95% CI, 1.00–2.56; p = 0.048) and LA enlargement (HR 1.07; 95% CI, 1.04–1.10; p < 0.001) predicted ERAT, whereas hypertrophic cardiomyopathy (HR 5.01; 95% CI, 2.20–11.42; p < 0.001) and LA enlargement (HR 1.04; 95% CI, 1.01–1.08; p = 0.019) predicted LRAT. In persistent AF, AF duration (HR 1.04; 95% CI, 1.02–1.06; p < 0.001) and LA enlargement (HR 1.03; 95% CI, 1.02–1.04; p < 0.001) predicted ERAT, and LA enlargement (HR 1.03; 95% CI, 1.01–1.05; p = 0.010) independently predicted LRAT. Conclusion: Predictors of ERAT and LRAT differed between patients with paroxysmal and those with persistent AF. LA enlargement was the most consistently shared predictor across recurrence phenotypes.
- 6 September 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Predictors of Early Versus Late Atrial Tachyarrhythmia Recurrence After Cryoballoon Ablation by Atrial Fibrillation Type
Introduction: Patient characteristics and predictors of early (ERAT) and late (LRAT) recurrence of atrial tachyarrhythmia by atrial fibrillation (AF) type after cryoballoon ablation (CBA) remain poorly defined. Methods: Using the Korean Heart Rhythm Cryoballoon Registry (12 centers, 2018–2022), 2051 patients undergoing CBA for drug‐refractory AF were stratified by AF type. ERAT was defined as atrial tachyarrhythmia within the 3‐month blanking period and LRAT as recurrence beyond 3 months. Independent predictors of ERAT (all patients) and LRAT (patients without ERAT) were identified. Results: ERAT occurred in 631 patients (30.8%; 17.6% in paroxysmal and 40.4% in persistent AF). Among 1420 patients without ERAT, LRAT occurred in 311 (21.9%; 16.7% paroxysmal, 27.2% persistent). In paroxysmal AF, coronary artery disease (HR 1.60; 95% CI, 1.00–2.56; p = 0.048) and LA enlargement (HR 1.07; 95% CI, 1.04–1.10; p < 0.001) predicted ERAT, whereas hypertrophic cardiomyopathy (HR 5.01; 95% CI, 2.20–11.42; p < 0.001) and LA enlargement (HR 1.04; 95% CI, 1.01–1.08; p = 0.019) predicted LRAT. In persistent AF, AF duration (HR 1.04; 95% CI, 1.02–1.06; p < 0.001) and LA enlargement (HR 1.03; 95% CI, 1.02–1.04; p < 0.001) predicted ERAT, and LA enlargement (HR 1.03; 95% CI, 1.01–1.05; p = 0.010) independently predicted LRAT. Conclusion: Predictors of ERAT and LRAT differed between patients with paroxysmal and those with persistent AF. LA enlargement was the most consistently shared predictor across recurrence phenotypes.
- 1 February 2026
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 25 (3) , 573-580
Efficacy and safety of operator-directed, nurse-administered propofol sedation in atrial fibrillation ablation
Aims: Adequate sedation and analgesia are essential for catheter ablation of atrial fibrillation (AF) to ensure patient comfort and procedural safety. However, the availability of cardiac anaesthesiology is limited. This study evaluated the efficacy and safety of an operator-directed, nurse-administered (ODNA) sedation protocol using propofol and remifentanil during AF ablation. Methods and results: In this prospective, single-centre observational cohort study, consecutive patients undergoing catheter ablation for AF from August 2023 to March 2024 were enrolled. Sedation-related adverse events and intra-procedural vital signs were recorded. Sedation depth was assessed using the Modified Observer’s Alertness/Sedation (MOAA/S) scale, and patient satisfaction was evaluated using the Visual Analogue Scale (VAS). A total of 230 patients were included (mean age 61.9 years; 76.1% male). Of these, 7.4% had a body mass index of ≥30 kg/m2, and 4.3% had obstructive sleep apnoea. Paroxysmal AF accounted for 30.9%, and the mean procedure time was 174 min. The primary outcome—defined as unplanned sedation interruption, intubation, or continuous vasopressor requirement—occurred in 2.2% of patients. Intermittent hypotension (mean arterial pressure: <60 mmHg) occurred in 36.1% of patients, but no patient required continuous vasopressors. The mean MOAA/S score was 0.4 ± 0.4. Post-procedural surveys showed high satisfaction (mean VAS: 8.8) and low maximal pain (VAS: 0.9). Conclusion: An ODNA protocol using propofol and remifentanil provides effective and safe sedation for AF ablation, with high patient satisfaction and minimal serious adverse events.
- 1 February 2026
- Published by Oxford University Press (OUP) in European Journal of Cardiovascular Nursing
- Vol. 25 (3) , 573-580
Efficacy and safety of operator-directed, nurse-administered propofol sedation in atrial fibrillation ablation
Aims: Adequate sedation and analgesia are essential for catheter ablation of atrial fibrillation (AF) to ensure patient comfort and procedural safety. However, the availability of cardiac anaesthesiology is limited. This study evaluated the efficacy and safety of an operator-directed, nurse-administered (ODNA) sedation protocol using propofol and remifentanil during AF ablation. Methods and results: In this prospective, single-centre observational cohort study, consecutive patients undergoing catheter ablation for AF from August 2023 to March 2024 were enrolled. Sedation-related adverse events and intra-procedural vital signs were recorded. Sedation depth was assessed using the Modified Observer’s Alertness/Sedation (MOAA/S) scale, and patient satisfaction was evaluated using the Visual Analogue Scale (VAS). A total of 230 patients were included (mean age 61.9 years; 76.1% male). Of these, 7.4% had a body mass index of ≥30 kg/m2, and 4.3% had obstructive sleep apnoea. Paroxysmal AF accounted for 30.9%, and the mean procedure time was 174 min. The primary outcome—defined as unplanned sedation interruption, intubation, or continuous vasopressor requirement—occurred in 2.2% of patients. Intermittent hypotension (mean arterial pressure: <60 mmHg) occurred in 36.1% of patients, but no patient required continuous vasopressors. The mean MOAA/S score was 0.4 ± 0.4. Post-procedural surveys showed high satisfaction (mean VAS: 8.8) and low maximal pain (VAS: 0.9). Conclusion: An ODNA protocol using propofol and remifentanil provides effective and safe sedation for AF ablation, with high patient satisfaction and minimal serious adverse events.
- Open Access
- 27 March 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (6) , 1253-1263
Comparison of Clinical Outcomes Between Left Bundle Branch Area Pacing With a Stylet‐Driven Lead and Conventional Right Ventricular Pacing
Backgrounds and Aims: Left bundle branch area pacing (LBBAP) has been shown to reduce the risk of pacing‐facilitated heart failure (HF) compared to right ventricular pacing (RVP), but limited data exists comparing LBBAP with stylet‐driven leads (SDL) and conventional RVP. The study aims to compare clinical outcomes between LBBAP using SDL and conventional RVP.Methods: From December 2018 to December 2023, patients who underwent pacemaker implantation at two tertiary hospitals were enrolled. Exclusions included those requiring cardiac resynchronization therapy and patients with ventricular pacing burden ≤ 10%. LBBAP was performed using SDL (Solia S60, Biotronik) with a fixed curve delivery sheath. Composite outcome I consisted of HF admission, pacing‐induced cardiomyopathy (defined as an LVEF decline of ≥ 10% or below 50%), and upgrade to biventricular pacing. Composite outcome II included all‐cause death in addition to the components of composite outcome I.Results: A total of 738 patients (mean age 72.1 years; 52% of men; 243 LBBAP vs. 495 RVP) were included. Atrioventricular block was more common pacing indication in LBBAP group than RVP group (88.1% vs. 69.3%, p < 0.001). Compared to RVP group, ventricular pacing burden was higher in the LBBAP group (96% vs. 86%, p < 0.001). LBBAP was associated with a lower risk of composite outcome I and II compared to RVP (adjusted HR 0.27 [95% confidence interval 0.11–0.68], p = 0.006 for composite outcome I, aHR 0.41 [0.20–0.84], p = 0.015 for composite outcome II), mainly driven by a lower risk of pacing‐induced cardiomyopathy by 70%. There were no significant differences in procedure‐related complications.Conclusion: LBBAP with SDL was associated with a lower risk of adverse clinical outcomes compared to conventional RVP in patients requiring substantial ventricular pacing.
- 27 March 2025
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 36 (6) , 1253-1263
Open AccessComparison of Clinical Outcomes Between Left Bundle Branch Area Pacing With a Stylet‐Driven Lead and Conventional Right Ventricular Pacing
Backgrounds and Aims: Left bundle branch area pacing (LBBAP) has been shown to reduce the risk of pacing‐facilitated heart failure (HF) compared to right ventricular pacing (RVP), but limited data exists comparing LBBAP with stylet‐driven leads (SDL) and conventional RVP. The study aims to compare clinical outcomes between LBBAP using SDL and conventional RVP.Methods: From December 2018 to December 2023, patients who underwent pacemaker implantation at two tertiary hospitals were enrolled. Exclusions included those requiring cardiac resynchronization therapy and patients with ventricular pacing burden ≤ 10%. LBBAP was performed using SDL (Solia S60, Biotronik) with a fixed curve delivery sheath. Composite outcome I consisted of HF admission, pacing‐induced cardiomyopathy (defined as an LVEF decline of ≥ 10% or below 50%), and upgrade to biventricular pacing. Composite outcome II included all‐cause death in addition to the components of composite outcome I.Results: A total of 738 patients (mean age 72.1 years; 52% of men; 243 LBBAP vs. 495 RVP) were included. Atrioventricular block was more common pacing indication in LBBAP group than RVP group (88.1% vs. 69.3%, p < 0.001). Compared to RVP group, ventricular pacing burden was higher in the LBBAP group (96% vs. 86%, p < 0.001). LBBAP was associated with a lower risk of composite outcome I and II compared to RVP (adjusted HR 0.27 [95% confidence interval 0.11–0.68], p = 0.006 for composite outcome I, aHR 0.41 [0.20–0.84], p = 0.015 for composite outcome II), mainly driven by a lower risk of pacing‐induced cardiomyopathy by 70%. There were no significant differences in procedure‐related complications.Conclusion: LBBAP with SDL was associated with a lower risk of adverse clinical outcomes compared to conventional RVP in patients requiring substantial ventricular pacing.
- Open Access
- 18 June 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (8) , 1614-1623
Long‐term clinical impact of early recurrence of atrial tachyarrhythmia after cryoballoon ablation in patients with atrial fibrillation
Introduction: The impact of early recurrence of atrial tachyarrhythmia (ERAT) within the 90‐day blanking period on long‐term outcomes in atrial fibrillation (AF) patients undergoing cryoballoon ablation (CBA) is controversial. This study aimed to assess the relationship between ERAT and late recurrence of atrial tachyarrhythmia (LRAT) post‐CBA.Methods: Utilizing data from a multicenter registry in Korea (May 2018 to June 2022), we analyzed the presence and timing of ERAT (p < .001). Multivariate analysis identified ERAT as a potential predictor of LRAT, with a hazard ratio (HR) of 3.98 (95% confidence interval [CI], 3.47–4.57). Significant associations were noted across all examined time frames (HR, 3.84; 95% CI, 3.32–4.45 in <30 days, HR, 5.53; 95% CI, 4.13–7.42 in 30–60 days, and HR, 4.29; 95% CI, 3.12–5.89 in 60–90 days). This finding was consistently observed across all types of AF.Conclusion: ERAT during the 90‐day blanking period strongly predicts LRAT in AF patients undergoing CBA, indicating a need to reconsider the clinical significance of this period.
- 18 June 2024
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 35 (8) , 1614-1623
Open AccessLong‐term clinical impact of early recurrence of atrial tachyarrhythmia after cryoballoon ablation in patients with atrial fibrillation
Introduction: The impact of early recurrence of atrial tachyarrhythmia (ERAT) within the 90‐day blanking period on long‐term outcomes in atrial fibrillation (AF) patients undergoing cryoballoon ablation (CBA) is controversial. This study aimed to assess the relationship between ERAT and late recurrence of atrial tachyarrhythmia (LRAT) post‐CBA.Methods: Utilizing data from a multicenter registry in Korea (May 2018 to June 2022), we analyzed the presence and timing of ERAT (p < .001). Multivariate analysis identified ERAT as a potential predictor of LRAT, with a hazard ratio (HR) of 3.98 (95% confidence interval [CI], 3.47–4.57). Significant associations were noted across all examined time frames (HR, 3.84; 95% CI, 3.32–4.45 in <30 days, HR, 5.53; 95% CI, 4.13–7.42 in 30–60 days, and HR, 4.29; 95% CI, 3.12–5.89 in 60–90 days). This finding was consistently observed across all types of AF.Conclusion: ERAT during the 90‐day blanking period strongly predicts LRAT in AF patients undergoing CBA, indicating a need to reconsider the clinical significance of this period.
- Open Access
- 30 June 2021
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 36 (3) , 688-696
Descriptive Epidemiology and Survival Analysis of Prolactinomas and Cushing’s Disease in Korea
Only a few studies have established the epidemiology of prolactinoma and Cushing's disease in Korea. Furthermore, the incidence of these disease are increasing than before associated with the development of technologies. This study was designed to evaluate the epidemiology of prolactinoma and Cushing's disease and their survival analysis according to treatment. The nationwide, population-based study evaluated incidence and prevalence of prolactinoma and Cushing's disease using de-identified claims data in The Korean Health Insurance Review and Assessment Service database between 2013 and 2017. The survival analysis investigated regarding treatment over a period of 6 years. A log-rank test and Cox proportional hazard regression analysis were used. The 6,056 patients with newly diagnosed prolactinoma and 584 patients with Cushing's disease were recorded between 2013 and 2017. The annual incidence of prolactinoma was 23.5 cases per million, and its prevalence was 82.5 cases per million, and 2.3 cases per million/year and 9.8 cases per million for Cushing's disease. The survival benefit was insignificant in prolactinoma according to treatment, but treatment of Cushing's disease ameliorated the survival rate significantly. Overall, the incidence of prolactinoma and Cushing's disease was similar with those found previously, but the prevalence of two diseases were inconsistent when compared with the early studies. The present study also proposed necessity of treatment in Cushing's disease for improving the survival rate.
- 30 June 2021
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 36 (3) , 688-696
Open AccessDescriptive Epidemiology and Survival Analysis of Prolactinomas and Cushing’s Disease in Korea
Only a few studies have established the epidemiology of prolactinoma and Cushing's disease in Korea. Furthermore, the incidence of these disease are increasing than before associated with the development of technologies. This study was designed to evaluate the epidemiology of prolactinoma and Cushing's disease and their survival analysis according to treatment. The nationwide, population-based study evaluated incidence and prevalence of prolactinoma and Cushing's disease using de-identified claims data in The Korean Health Insurance Review and Assessment Service database between 2013 and 2017. The survival analysis investigated regarding treatment over a period of 6 years. A log-rank test and Cox proportional hazard regression analysis were used. The 6,056 patients with newly diagnosed prolactinoma and 584 patients with Cushing's disease were recorded between 2013 and 2017. The annual incidence of prolactinoma was 23.5 cases per million, and its prevalence was 82.5 cases per million, and 2.3 cases per million/year and 9.8 cases per million for Cushing's disease. The survival benefit was insignificant in prolactinoma according to treatment, but treatment of Cushing's disease ameliorated the survival rate significantly. Overall, the incidence of prolactinoma and Cushing's disease was similar with those found previously, but the prevalence of two diseases were inconsistent when compared with the early studies. The present study also proposed necessity of treatment in Cushing's disease for improving the survival rate.